Pancreatic Cancer Research

ResearcherColumbia UniversityNo recent work listed

Chung Yin Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6431-7830; OpenAlex author ID A5009216690; NIH RePORTER profile ID 8696616. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
25
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 3 papers · 2020: none · 2021: 1 grant · 2022: 1 paper

Papers 10

  1. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Co-author DOI 10.1002/cnr2.1565↗
  2. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Last author DOI 10.1097/md.0000000000018082↗
  3. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. Co-author DOI 10.1371/journal.pone.0215409↗
  4. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Co-author DOI 10.1634/theoncologist.2018-0114↗
  5. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Co-author DOI 10.1002/cam4.1277↗
  6. Patterns and predictors of end-of-life care in older patients with pancreatic cancer. Co-author DOI 10.1002/cam4.1861↗
  7. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Co-author DOI 10.1016/j.pan.2018.07.009↗
  8. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Co-author DOI 10.1097/mpa.0000000000000587↗
  9. Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. Co-author DOI 10.1016/j.ebiom.2015.11.005↗
  10. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Co-author DOI 10.1148/radiol.14141282↗

Grants 1

  1. Optimizing the Treatment of Pancreatic Adenocarcinoma R01CA212086↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chin Hur · 10 shared papers, 1 shared grant, 2015–2022 · strength 1.42
  2. Angela C. Tramontano · 8 shared papers, 2015–2019 · strength 0.66
  3. Pari V. Pandharipande · 7 shared papers, 2015–2019 · strength 0.52
  4. Ryan David Nipp · 3 shared papers, 2018–2019 · strength 0.29
  5. Mary Linton B. Peters · 2 shared papers, 2018–2019 · strength 0.18
  6. Deborah Schrag · 2 shared papers, 2018–2019 · strength 0.17
  7. William Robert Brugge · 3 shared papers, 2015–2016 · strength 0.16
  8. Susan Elaine Bates · 1 shared paper, 2022 · strength 0.15
  9. Myles A. Ingram · 1 shared paper, 2022 · strength 0.15
  10. Jiheum Park · 1 shared paper, 2022 · strength 0.15
  11. Gulam Abbas Manji · 1 shared paper, 2022 · strength 0.15
  12. Fay Kastrinos · 1 shared paper, 2022 · strength 0.15
  13. Theodore Sunki Hong · 1 shared paper, 2019 · strength 0.08
  14. Carlos F. Fernandez-del Castillo · 1 shared paper, 2019 · strength 0.08
  15. Jin Choi · 1 shared paper, 2019 · strength 0.08
  16. David P. Ryan · 1 shared paper, 2019 · strength 0.08
  17. Cristina Rosa Ferrone · 1 shared paper, 2019 · strength 0.08
  18. Kimiyo N. Yamamoto · 1 shared paper, 2019 · strength 0.08
  19. Akira Nakamura · 1 shared paper, 2019 · strength 0.08
  20. Tetsunosuke Shimizu · 1 shared paper, 2019 · strength 0.08
  21. Kazuhisa Uchiyama · 1 shared paper, 2019 · strength 0.08
  22. Franziska Michor A · 1 shared paper, 2019 · strength 0.08
  23. Hiroshi Haeno · 1 shared paper, 2019 · strength 0.08
  24. Gabriel A. Brooks · 1 shared paper, 2016 · strength 0.06
  25. Daniel C. Chung · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.